TLSA — Tiziana Life Sciences Ltd

Is TLSA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Tiziana Life Sciences Ltd (TLSA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.58. The rating moved from Strong Oversold to Oversold on October 31, 2026.

See all oversold Healthcare stocks →

AI analysis

Tiziana Life Sciences Ltd (TLSA) is a small, clinical-stage biotech with valuation driven by binary clinical and corporate events. Financial health is likely constrained by typical cash-burn dynamics for peers, making near-term financing or partnership activity a key determinant of the share trajectory. The company benefits from upside potential tied to positive clinical readouts or licensing but faces meaningful dilution, liquidity and execution risks; sector flows favoring large-cap pharma add headwinds to speculative names.

Key factors

  • Small-cap clinical-stage biotech profile with a pipeline focused on oncology/immunology (binary clinical catalysts drive valuation)
  • Limited public financial disclosure in the prompt and typical high cash-burn dynamics for peers imply dependence on near-term financing or partnering
  • High volatility and low liquidity typical of microcap biotechs increase execution and market-risk for shareholders
  • Sector environment favors large-cap pharma defensive flows, which can reduce investor appetite for speculative mid-/small-cap biotech exposure
  • Convertible-debt and financing trends in the sector increase dilution risk for mid-cap/biotech issuers
  • Potential upside from positive clinical readouts, licensing deals, or strategic partnerships that can materially re-rate equity

Risks

  • Clinical-trial setbacks, negative efficacy/safety readouts or regulatory delays for lead programs
  • Near-term cash runway shortfall requiring dilutive equity raises, debt financing or unfavorable partnerships
  • High shareholder dilution risk given sector financing dynamics (convertible debt or emergency financings)
  • Low trading liquidity and high share-price volatility, complicating investor entry/exit and leading to outsized moves on news
  • Adverse shifts in investor preference toward large-cap pharma and defensive healthcare, reducing appetite for speculative names
  • Competition from better-capitalized companies or alternative therapeutic approaches that could limit commercial opportunity

See today's live rating, score and targets

Members see the live hourly rating for TLSA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.